Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-25-283021
Filing Date
2025-11-14
Accepted
2025-11-14 16:18:52
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 16620
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 71468
  Complete submission text file 0001193125-25-283021.txt   116950
Mailing Address 131 OYSTER POINT BLVD., SUITE 600 SOUTH SAN FRANCISCO CA 94080
Business Address 131 OYSTER POINT BLVD., SUITE 600 SOUTH SAN FRANCISCO CA 94080 415-231-5660
Alector, Inc. (Subject) CIK: 0001653087 (see all company filings)

EIN.: 822933343 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90858 | Film No.: 251486642
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 245 LYTTON AVE., SUITE 350 PALO ALTO CA
Business Address 245 LYTTON AVE., SUITE 350 PALO ALTO CA 650-924-9424
TCG Crossover GP II, LLC (Filed by) CIK: 0001969280 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G